journal article·2023-01

Aggregation‐Induced‐Emission Photosensitizer‐Loaded Nano‐Superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy

Zhihong Sun, Jie Liu, Yueying Li, Xun lin, Yongli Chu, Wenting Wang, Shiyun Huang, Wei Li, Jin Peng, Chuyao Liu, Lintao Cai, Wenbin Deng, Chengming Sun, Guanjun Deng

Advanced Materials· Volume 35· Issue 3
Publisher page

Abstract

Abstract The success of tumor immunotherapy highlights the potential of harnessing immune system to fight cancer. Activating both native T cells and exhausted T cells is a critical step for generating effective antitumor immunity, which is determined based on the efficient presentation of tumor antigens and co‐stimulatory signals by antigen‐presenting cells, as well as immunosuppressive reversal. However, strategies for achieving an efficient antigen presentation process and improving the immunosuppressive microenvironment remain unresolved. Here, aggregation‐induced‐emission (AIE) photosensitizer‐loaded nano‐superartificial dendritic cells (saDC@Fs‐NPs) are developed by coating superartificial dendritic cells membranes from genetically engineered 4T1 tumor cells onto nanoaggregates of AIE photosensitizers. The outer cell membranes of saDC@Fs‐NPs are derived from recombinant lentivirus‐infected 4T1 tumor cells in which peptide‐major histocompatibility complex class I, CD86, and anti‐LAG3 antibody are simultaneously anchored. These saDC@Fs‐NPs could directly stimulate T‐cell activation and reverse T‐cell exhaustion for cancer immunotherapy. The inner AIE‐active photosensitizers induce immunogenic cell death to activate dendritic cells and enhance T lymphocyte infiltration by photodynamic therapy, promoting the transformation of “cold tumors” into “hot tumors,” which further boosts immunotherapy efficiency. This work presents a powerful photoactive and artificial antigen‐presenting platform for activating both native T cells and exhausted T cells, as well as facilitating tumor photodynamic immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences (Shenzhen) Sun Yat‐sen University Shenzhen 518107 P. R. China

The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai 264000 P. R. China

Guangdong Key Laboratory of Nanomedicine Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations CAS‐HK Joint Lab for Biomaterials, CAS Key Lab for Health Informatics Institute of Biomedicine and Biotechnology Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences Shenzhen 518055 P. R. China

Funding

National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.1038/s41586-019-1593-510.1038/s41586-019-1593-5 ↗
2. 10.1038/s41586-022-04632-110.1038/s41586-022-04632-1 ↗
3. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
4. 10.1038/s41568-021-00347-z10.1038/s41568-021-00347-z ↗
5. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
6. 10.1038/s41568-021-00339-z10.1038/s41568-021-00339-z ↗
7. 10.1038/s41568-020-0273-y10.1038/s41568-020-0273-y ↗
8. 10.1038/s41573-020-0081-910.1038/s41573-020-0081-9 ↗
9. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
10. 10.1038/s41467-018-03915-410.1038/s41467-018-03915-4 ↗
11. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
12. 10.1038/s41577-021-00574-310.1038/s41577-021-00574-3 ↗
13. 10.1038/s41592-020-0867-z10.1038/s41592-020-0867-z ↗
14. 10.1002/adma.20210232210.1002/adma.202102322 ↗
15. 10.1021/acs.nanolett.0c0478310.1021/acs.nanolett.0c04783 ↗
16. 10.1016/j.molimm.2018.02.01610.1016/j.molimm.2018.02.016 ↗
17. 10.1016/j.it.2016.09.00610.1016/j.it.2016.09.006 ↗
18. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
19. 10.1038/nrclinonc.2016.2510.1038/nrclinonc.2016.25 ↗
20. Lancet O. T. · Lancet Oncol. · 2021 · 22
21. 10.1038/s41551-021-00800-210.1038/s41551-021-00800-2 ↗
22. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
23. 10.1016/j.immuni.2021.10.02010.1016/j.immuni.2021.10.020 ↗
24. 10.1038/s41586-020-2229-510.1038/s41586-020-2229-5 ↗
25. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
26. 10.1002/adma.20170711210.1002/adma.201707112 ↗
27. Liang S. · Adv. Funct. Mater. · 2021
28. 10.1002/adfm.20201077710.1002/adfm.202010777 ↗
29. 10.1016/j.smim.2019.10130510.1016/j.smim.2019.101305 ↗
30. 10.1016/j.immuni.2016.05.00110.1016/j.immuni.2016.05.001 ↗
31. 10.1111/imr.1251910.1111/imr.12519 ↗
32. 10.1038/d41573-022-00036-y10.1038/d41573-022-00036-y ↗
33. 10.1016/j.biomaterials.2022.12143310.1016/j.biomaterials.2022.121433 ↗
34. 10.1002/adma.20200777810.1002/adma.202007778 ↗
35. 10.1002/adma.20210397810.1002/adma.202103978 ↗
36. 10.1002/adhm.20210105510.1002/adhm.202101055 ↗
37. 10.1002/adhm.20210105610.1002/adhm.202101056 ↗
38. 10.1002/adma.20180135010.1002/adma.201801350 ↗
39. 10.1002/anie.20200589910.1002/anie.202005899 ↗
40. 10.1002/adfm.20220537110.1002/adfm.202205371 ↗
41. 10.1021/acsnano.0c0382410.1021/acsnano.0c03824 ↗
42. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
43. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
44. 10.1016/j.biomaterials.2021.12122810.1016/j.biomaterials.2021.121228 ↗
45. 10.1002/adma.20210141010.1002/adma.202101410 ↗
46. 10.1016/j.trecan.2020.02.02210.1016/j.trecan.2020.02.022 ↗
47. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
48. 10.1002/adma.20210665410.1002/adma.202106654 ↗
49. 10.1002/anie.20180488210.1002/anie.201804882 ↗
50. 10.1016/j.chempr.2017.05.01010.1016/j.chempr.2017.05.010 ↗
51. 10.1021/jacs.9b0716210.1021/jacs.9b07162 ↗
52. 10.1038/s41467-018-04222-810.1038/s41467-018-04222-8 ↗
53. 10.1039/C7SC04963C10.1039/C7SC04963C ↗
54. 10.1016/j.cell.2022.01.00810.1016/j.cell.2022.01.008 ↗
55. 10.1021/acsnano.8b0437110.1021/acsnano.8b04371 ↗
56. 10.1021/acsnano.8b0529210.1021/acsnano.8b05292 ↗
57. 10.1038/nbt.404710.1038/nbt.4047 ↗
58. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
59. 10.1002/advs.20210071210.1002/advs.202100712 ↗
60. 10.1038/s41590-017-0022-x10.1038/s41590-017-0022-x ↗
61. 10.1038/ncomms1319310.1038/ncomms13193 ↗
62. 10.1126/sciadv.abb311610.1126/sciadv.abb3116 ↗